Echo Therapeutics (OTCMKTS: ECTE) and Innovus Pharmaceuticals (OTCMKTS:INNV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.
This table compares Echo Therapeutics and Innovus Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current recommendations for Echo Therapeutics and Innovus Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Risk and Volatility
Echo Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500. Comparatively, Innovus Pharmaceuticals has a beta of 4.02, suggesting that its share price is 302% more volatile than the S&P 500.
Valuation and Earnings
This table compares Echo Therapeutics and Innovus Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Echo Therapeutics||N/A||N/A||-$22.19 million||N/A||N/A|
|Innovus Pharmaceuticals||$4.82 million||3.00||-$13.70 million||($0.07)||-1.26|
Innovus Pharmaceuticals has higher revenue and earnings than Echo Therapeutics.
Echo Therapeutics Company Profile
Echo Therapeutics, Inc. is a medical device company. The Company is engaged in developing a non-invasive, wireless continuous glucose monitoring (CGM) system with use in the wearable-health consumer market, diabetes outpatient market and in the hospital setting. The Company operates through the development of transdermal skin permeation and diagnostic medical devices segment. The Company has also developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, enhanced delivery of topical pharmaceuticals and other applications. The CGM System includes a skin preparation device, transdermal glucose sensor, battery and wireless transmitter. The Company has conducted several human feasibility clinical studies with its CGM System in healthy subjects, diabetics and critically ill patients, as well as a clinical study at several hospitals in the United States.
Innovus Pharmaceuticals Company Profile
Innovus Pharmaceuticals, Inc. is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It has commercial agreements in over 60 countries around the world through its commercial partners. Its marketed products include Zestra, EjectDelay, Sensum+, Zestra Glide, Vesele and Androferti. In addition, the Company has a pipeline of over three additional products, including FlutiCare Over-The-Counter (OTC) for Allergic Rhinitis; Urocis XR, an extended release of Vaccinium Marcocarpon (cranberry), and AndroVit, a supplement to support overall prostate and male sexual health, which is marketed in Europe.
Receive News & Ratings for Echo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Echo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.